Tinnn personal page - To The Moon

Tinnn

Tinnn

No personal profile

10Follow

1Followers

0Topic

0Badge

2021-02-04

$Atossa Genetics(ATOS)$Let’s go good news bout phase 2 let get more catalyst soon!

2021-02-03

Looking promising

BRIEF-Atossa Therapeutics’ Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study To Be Halted Early

2021-02-03

$Gevo(GEVO)$Very high confidence about this one ?

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3572214037167138","uuid":"3572214037167138","gmtCreate":1609120145623,"gmtModify":1612307635005,"name":"Tinnn","pinyin":"tinnn","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/9e332204b0cbcb78a521c9b8860e3b89","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":10,"tweetSize":3,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.68%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":317989308,"gmtCreate":1612406497404,"gmtModify":1704870735928,"author":{"id":"3572214037167138","authorId":"3572214037167138","name":"Tinnn","avatar":"https://static.tigerbbs.com/9e332204b0cbcb78a521c9b8860e3b89","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572214037167138","authorIdStr":"3572214037167138"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Let’s go good news bout phase 2 let get more catalyst soon!","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Let’s go good news bout phase 2 let get more catalyst soon!","text":"$Atossa Genetics(ATOS)$Let’s go good news bout phase 2 let get more catalyst soon!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/317989308","isVote":1,"tweetType":1,"viewCount":273,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":314803015,"gmtCreate":1612326312637,"gmtModify":1704869761717,"author":{"id":"3572214037167138","authorId":"3572214037167138","name":"Tinnn","avatar":"https://static.tigerbbs.com/9e332204b0cbcb78a521c9b8860e3b89","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572214037167138","authorIdStr":"3572214037167138"},"themes":[],"htmlText":"Looking promising","listText":"Looking promising","text":"Looking promising","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/314803015","repostId":"2108416735","repostType":2,"repost":{"id":"2108416735","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1612276360,"share":"https://ttm.financial/m/news/2108416735?lang=&edition=fundamental","pubTime":"2021-02-02 22:32","market":"us","language":"en","title":"BRIEF-Atossa Therapeutics’ Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study To Be Halted Early","url":"https://stock-news.laohu8.com/highlight/detail?id=2108416735","media":"Reuters","summary":"Feb 2 (Reuters) - Atossa Therapeutics Inc   :   * ATOSSA THERAPEUTICS’ PHASE 2 ENDOXIFEN BREAST CANC","content":"<html><body><p>Feb 2 (Reuters) - Atossa Therapeutics Inc   :</p><p>   * ATOSSA THERAPEUTICS’ PHASE 2 ENDOXIFEN BREAST CANCER STUDY PRODUCES SUBSTANTIALLY POSITIVE RESULTS ALLOWING STUDY TO BE HALTED EARLY</p><p>   * ATOSSA THERAPEUTICS - ACCELERATING ITS ENDOXIFEN PROGRAM IN UNITED STATES</p><p>   * ATOSSA THERAPEUTICS - EVALUATING NUMBER OF POTENTIAL CLINICAL BENEFITS, POTENTIAL INDICATIONS FOR ORAL ENDOXIFEN IN WINDOW OF OPPORTUNITY SETTING</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Atossa Therapeutics’ Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study To Be Halted Early</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Atossa Therapeutics’ Phase 2 Endoxifen Breast Cancer Study Produces Substantially Positive Results Allowing Study To Be Halted Early\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-02-02 22:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Feb 2 (Reuters) - Atossa Therapeutics Inc   :</p><p>   * ATOSSA THERAPEUTICS’ PHASE 2 ENDOXIFEN BREAST CANCER STUDY PRODUCES SUBSTANTIALLY POSITIVE RESULTS ALLOWING STUDY TO BE HALTED EARLY</p><p>   * ATOSSA THERAPEUTICS - ACCELERATING ITS ENDOXIFEN PROGRAM IN UNITED STATES</p><p>   * ATOSSA THERAPEUTICS - EVALUATING NUMBER OF POTENTIAL CLINICAL BENEFITS, POTENTIAL INDICATIONS FOR ORAL ENDOXIFEN IN WINDOW OF OPPORTUNITY SETTING</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ATOS":"Atossa Genetics Inc"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2108416735","content_text":"Feb 2 (Reuters) - Atossa Therapeutics Inc   :   * ATOSSA THERAPEUTICS’ PHASE 2 ENDOXIFEN BREAST CANCER STUDY PRODUCES SUBSTANTIALLY POSITIVE RESULTS ALLOWING STUDY TO BE HALTED EARLY   * ATOSSA THERAPEUTICS - ACCELERATING ITS ENDOXIFEN PROGRAM IN UNITED STATES   * ATOSSA THERAPEUTICS - EVALUATING NUMBER OF POTENTIAL CLINICAL BENEFITS, POTENTIAL INDICATIONS FOR ORAL ENDOXIFEN IN WINDOW OF OPPORTUNITY SETTINGSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":22,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":314125814,"gmtCreate":1612322241438,"gmtModify":1704869714115,"author":{"id":"3572214037167138","authorId":"3572214037167138","name":"Tinnn","avatar":"https://static.tigerbbs.com/9e332204b0cbcb78a521c9b8860e3b89","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572214037167138","authorIdStr":"3572214037167138"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GEVO\">$Gevo(GEVO)$</a>Very high confidence about this one ?","listText":"<a href=\"https://laohu8.com/S/GEVO\">$Gevo(GEVO)$</a>Very high confidence about this one ?","text":"$Gevo(GEVO)$Very high confidence about this one ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/314125814","isVote":1,"tweetType":1,"viewCount":87,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"idStr":"3527667803686145","authorIdStr":"3527667803686145"},"content":"Finally, when you first post [compare heart] [compare heart] post, you can get more exposure by related stocks or related topics. If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation","text":"Finally, when you first post [compare heart] [compare heart] post, you can get more exposure by related stocks or related topics. If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation","html":"Finally, when you first post [compare heart] [compare heart] post, you can get more exposure by related stocks or related topics. If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation"}],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":317989308,"gmtCreate":1612406497404,"gmtModify":1704870735928,"author":{"id":"3572214037167138","authorId":"3572214037167138","name":"Tinnn","avatar":"https://static.tigerbbs.com/9e332204b0cbcb78a521c9b8860e3b89","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572214037167138","authorIdStr":"3572214037167138"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Let’s go good news bout phase 2 let get more catalyst soon!","listText":"<a href=\"https://laohu8.com/S/ATOS\">$Atossa Genetics(ATOS)$</a>Let’s go good news bout phase 2 let get more catalyst soon!","text":"$Atossa Genetics(ATOS)$Let’s go good news bout phase 2 let get more catalyst soon!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/317989308","isVote":1,"tweetType":1,"viewCount":273,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":314125814,"gmtCreate":1612322241438,"gmtModify":1704869714115,"author":{"id":"3572214037167138","authorId":"3572214037167138","name":"Tinnn","avatar":"https://static.tigerbbs.com/9e332204b0cbcb78a521c9b8860e3b89","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572214037167138","authorIdStr":"3572214037167138"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/GEVO\">$Gevo(GEVO)$</a>Very high confidence about this one ?","listText":"<a href=\"https://laohu8.com/S/GEVO\">$Gevo(GEVO)$</a>Very high confidence about this one ?","text":"$Gevo(GEVO)$Very high confidence about this one ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/314125814","isVote":1,"tweetType":1,"viewCount":87,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"idStr":"3527667803686145","authorIdStr":"3527667803686145"},"content":"Finally, when you first post [compare heart] [compare heart] post, you can get more exposure by related stocks or related topics. If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation","text":"Finally, when you first post [compare heart] [compare heart] post, you can get more exposure by related stocks or related topics. If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation","html":"Finally, when you first post [compare heart] [compare heart] post, you can get more exposure by related stocks or related topics. If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":314803015,"gmtCreate":1612326312637,"gmtModify":1704869761717,"author":{"id":"3572214037167138","authorId":"3572214037167138","name":"Tinnn","avatar":"https://static.tigerbbs.com/9e332204b0cbcb78a521c9b8860e3b89","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572214037167138","authorIdStr":"3572214037167138"},"themes":[],"htmlText":"Looking promising","listText":"Looking promising","text":"Looking promising","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/314803015","repostId":"2108416735","repostType":2,"isVote":1,"tweetType":1,"viewCount":22,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}